Lupin has received approval for its Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg from the United States Food and Drug Administration (USFDA). Lupin’s Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, is the generic version of Sensipar Tablets, 30 mg, 60 mg, and 90 mg, of Amgen Inc.
It is indicated in the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, hypercalcemia in adult patients with Parathyroid Carcinoma. Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, had annual sales of approximately $1,527 million in the US (IQVIA MAT March 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
